arrow
L

Laura De Michieli

University of Padua
H指数:16
被引数:929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pattern of use of conventional medical treatments of heart failure with reduced ejection fraction in end-stage hypertrophic cardiomyopathy

射血分数降低的心力衰竭在终末期肥厚型心肌病中常规医疗治疗的用药模式

2026-08-010
OA
Cardiac Troponin in Autoimmune Rheumatic Diseases: Lights and Shadows

自身免疫性风湿性疾病中的心肌肌钙蛋白:利弊与挑战

2026-07-310
OAAI
Serum Transthyretin Before and After Starting Tafamidis as Outcome Predictors in ATTR Cardiomyopathy

血清甲状腺素结合前白蛋白在 ATTR 心肌病中作为起始塔夫米迪斯治疗前后结局预测因子

JACC
IF0
2026-02-180
PRE
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis

野生型甲状腺素转运蛋白淀粉样变性心肌病真实世界患者接受tafamidis治疗后的临床表型与预后

2025-11-290
OAAI
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis

野生型甲状腺素运载蛋白心肌病NYHA功能分级I级和II级患者接受Tafamidis治疗后的结局与疾病进展

2025-07-030
OA
Reply

回复

2025-06-170
OAAI
Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis
2024-12-120
OA
Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis

基线及随访时的神经激素疗法与野生型甲状腺素运载蛋白心脏淀粉样变性患者的生存情况

2024-11-120
PRE
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study
2024-09-200
OA